{'fraction_non_alphanumeric': 0.016979445933869526, 'fraction_numerical': 0.006255585344057194, 'mean_word_length': 5.120218579234972, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Methylation markers in the clinical management of leukemia patients: wave of the future or just damp squib?

DNA methylation: a rich source of new molecular markers? Approximately 20 years ago, the suggestion that alterations in DNA methylation played a major causative role in cancer would likely have been met with a considerable amount of skepticism amongst many cancer researchers. However, in the last 20 years, driven by multiple new methodological developments, there has been exponential growth in the field of DNA methylation and cancer. It is now generally accepted that cancer is as much an epigenetic as a genetic disease [4]. DNA methylation has been at the forefront of this epigenetic revolution and essentially all types of cancer exhibit dramatic shifts in the pattern of DNA methylation in the cancer genome compared with its normal counterpart [5]. This in turn has led to great interest in whether differences in DNA methylation changes between cancer patients can be used as a rich new source of biological markers for predicting patient outcome and responses to different treatment approaches [6].